REFERENCES
1. Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, et al. A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J Thorac Oncol 2016;11:1690-700.
2. Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med 2015;7:293ra104.
3. Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, et al. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer 2006;95:1390-5.
4. De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martinez-Ricarte F, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 2015;6:8839.
5. Diehl F, Schmidt K, Durkee KH, Moore KJ, Goodman SN, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 2008;135:489-98.
7. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 2017;14:531-48.
8. Pantel K, Alix-Panabieres C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res 2013;73:6384-8.
9. Xi L, Belyaev A, Spurgeon S, Wang X, Gong H, et al. New library construction method for single-cell genomes. PLoS One 2017;12:e0181163.
10. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-5.
11. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
12. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54.
13. Li SC, Chan WC, Hu LY, Lai CH, Hsu CN, et al. Identification of homologous microRNAs in 56 animal genomes. Genomics 2010;96:1-9.
14. Friedlander MR, Lizano E, Houben AJ, Bezdan D, Banez-Coronel M, et al. Evidence for the biogenesis of more than 1,000 novel human microRNAs. Genome Biol 2014;15:R57.
16. Tan W, Liu B, Qu S, Liang G, Luo W, et al. MicroRNAs and cancer: key paradigms in molecular therapy. Oncol Lett 2018;15:2735-42.
17. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
18. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011;108:5003-8.
19. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, et al. Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 2008;14:27-41.
20. Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 2012;7:e30679.
21. Zhou Q, Li M, Wang X, Li Q, Wang T, et al. Immune-related microRNAs are abundant in breast milk exosomes. Int J Biol Sci 2012;8:118-23.
22. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010;56:1733-41.
23. Da Silveira J, Andrade GM, Perecin F, Meireles FV, Winger QA, et al. Isolation and Analysis of exosomal MicroRNAs from ovarian follicular fluid. Methods Mol Biol 2018;1733:53-63.
24. Cote GA, Gore AJ, McElyea SD, Heathers LE, Xu H, et al. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile. Am J Gastroenterol 2014;109:1942-52.
25. Roman-Canal B, Tarragona J, Moiola CP, Gatius S, Bonnin S, et al. EV-associated miRNAs from peritoneal lavage as potential diagnostic biomarkers in colorectal cancer. J Transl Med 2019;17:208.
26. Shigeyasu K, Toden S, Zumwalt TJ, Okugawa Y, Goel A. Emerging role of MicroRNAs as liquid biopsy biomarkers in gastrointestinal cancers. Clin Cancer Res 2017;23:2391-9.
27. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13:423-33.
28. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, et al. MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011;8:467-77.
29. Stark R, Grzelak M, Hadfield J. RNA sequencing: the teenage years. Nat Rev Genet 2019;20:631-56.
30. Pardini B, Calin GA. MicroRNAs and long non-coding RNAs and their hormone-like activities in cancer. Cancers (Basel) 2019;11.
31. Iftikhar H, Carney GE. Evidence and potential in vivo functions for biofluid miRNAs: from expression profiling to functional testing: potential roles of extracellular miRNAs as indicators of physiological change and as agents of intercellular information exchange. Bioessays 2016;38:367-78.
32. Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, et al. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res 2013;19:4477-87.
33. Sochor M, Basova P, Pesta M, Dusilkova N, Bartos J, et al. Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer 2014;14:448.
34. Roth C, Rack B, Muller V, Janni W, Pantel K, et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010;12:R90.
35. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 2010;15:673-82.
36. Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci 2016;107:326-34.
37. Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, et al. Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res 2016;18:90.
38. Li P, Dong J, Zhou X, Sun W, Huang H, et al. Expression patterns of microRNA-329 and its clinical performance in diagnosis and prognosis of breast cancer. Onco Targets Ther 2017;10:5711-8.
39. McAnena P, Tanriverdi K, Curran C, Gilligan K, Freedman JE, et al. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer. BMC Cancer 2019;19:436.
40. Tan W, Liang G, Xie X, Jiang W, Tan L, et al. Incorporating MicroRNA into molecular phenotypes of circulating tumor cells enhances the prognostic accuracy for patients with metastatic breast cancer. Oncologist 20191;24:e1044-54.
41. Shao B, Wang X, Zhang L, Li D, Liu X, et al. Plasma microRNAs predict chemoresistance in patients with metastatic breast cancer. Technol Cancer Res Treat 2019;18:1533033819828709.
42. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34.
43. Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013;258:619-26. discussion 26-7
44. Zimmitti G, Shindoh J, Mise Y, Kopetz S, Loyer EM, et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol 2015;22:834-42.
45. Choi HH, Cho YS, Choi JH, Kim HK, Kim SS, et al. Stool-Based miR-92a and miR-144* as Noninvasive Biomarkers for Colorectal Cancer Screening. Oncology 2019;97:173-9.
46. Yau TO, Tang CM, Harriss EK, Dickins B, Polytarchou C. Faecal microRNAs as a non-invasive tool in the diagnosis of colonic adenomas and colorectal cancer: a meta-analysis. Sci Rep 2019;9:9491.
47. Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 2010;19:1766-74.
48. Zhu M, Huang Z, Zhu D, Zhou X, Shan X, et al. A panel of microRNA signature in serum for colorectal cancer diagnosis. Oncotarget 2017;8:17081-91.
49. Wikberg ML, Myte R, Palmqvist R, van Guelpen B, Ljuslinder I. Plasma miRNA can detect colorectal cancer, but how early? Cancer Med 2018;7:1697-705.
50. Zanutto S, Pizzamiglio S, Ghilotti M, Bertan C, Ravagnani F, et al. Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer. Br J Cancer 2014;110:1001-7.
51. Wang S, Xiang J, Li Z, Lu S, Hu J, et al. A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer 2015;136:152-61.
52. Zanutto S, Ciniselli CM, Belfiore A, Lecchi M, Masci E, et al. Plasma miRNA-based signatures in CRC screening programs. Int J Cancer 2020;146:1164-73.
53. Karimi N, Ali Hosseinpour Feizi M, Safaralizadeh R, Hashemzadeh S, Baradaran B, et al. Serum overexpression of miR-301a and miR-23a in patients with colorectal cancer. J Chin Med Assoc 2019;82:215-20.
54. Pesta M, Kucera R, Topolcan O, Karlikova M, Houfkova K, et al. Plasma microRNA levels combined with CEA and CA19-9 in the follow-up of colorectal cancer patients. Cancers (Basel) 2019;11.
55. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011;6:e17745.
56. Ji D, Qiao M, Yao Y, Li M, Chen H, et al. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients. EBioMedicine 2018;35:189-97.
57. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9.
58. Feng F, Tian Y, Xu G, Liu Z, Liu S, et al. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. BMC Cancer 2017;17:737.
59. Cai H, Yuan Y, Hao YF, Guo TK, Wei X, et al. Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol 2013;30:452.
60. Zhu XL, Ren LF, Wang HP, Bai ZT, Zhang L, et al. Plasma microRNAs as potential new biomarkers for early detection of early gastric cancer. World J Gastroenterol 2019;25:1580-91.
61. Wu J, Li G, Wang Z, Yao Y, Chen R, et al. Circulating microRNA-21 is a potential diagnostic biomarker in gastric cancer. Dis Markers 2015;2015:435656.
62. Liu R, Zhang C, Hu Z, Li G, Wang C, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011;47:784-91.
63. Liu H, Zhu L, Liu B, Yang L, Meng X, et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett 2012;316:196-203.
64. Han X, Li X, Zhao H, Zhou D, Sun B, et al. Serum miR-515-3p, a potential new RNA biomarker, is involved in gastric carcinoma. J Cell Biochem 2019;120:15834-43.
65. Wang T, Zhang J, Tian J, Hu S, Wei R, et al. Low expression levels of plasma miR-141 are associated with susceptibility to gastric cancer. Oncol Lett 2019;18:629-36.
66. Hung PS, Chen CY, Chen WT, Kuo CY, Fang WL, et al. miR-376c promotes carcinogenesis and serves as a plasma marker for gastric carcinoma. PLoS One 2017;12:e0177346.
67. Iwasaki H, Shimura T, Yamada T, Okuda Y, Natsume M, et al. A novel urinary microRNA biomarker panel for detecting gastric cancer. J Gastroenterol 2019;54:1061-9.
68. Li X, Zhang Y, Zhang Y, Ding J, Wu K, et al. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2010;59:579-85.
69. Tsai MM, Wang CS, Tsai CY, Huang CG, Lee KF, et al. Circulating microRNA-196a/b are novel biomarkers associated with metastatic gastric cancer. Eur J Cancer 2016;64:137-48.
70. Wang N, Wang L, Yang Y, Gong L, Xiao B, et al. A serum exosomal microRNA panel as a potential biomarker test for gastric cancer. Biochem Biophys Res Commun 2017;493:1322-8.
71. Wang Q, Li P, Li A, Jiang W, Wang H, et al. Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res 2012;31:97.
72. Qu S, Guan J, Liu Y. Identification of microRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles. J Neurol Sci 2015;348:181-7.
73. van der Vos KE, Abels ER, Zhang X, Lai C, Carrizosa E, et al. Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro Oncol 2016;18:58-69.
74. Akers JC, Hua W, Li H, Ramakrishnan V, Yang Z, et al. A cerebrospinal fluid microRNA signature as biomarker for glioblastoma. Oncotarget 2017;8:68769-79.
75. Wang J, Che F, Zhang J. Cell-free microRNAs as non-invasive biomarkers in glioma: a diagnostic meta-analysis. Int J Biol Markers 2019;34:232-42.
76. Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, et al. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med 2007;45:1169-79.
77. Mokdad AA, Hester CA, Singal AG, Yopp AC. Management of hepatocellular in the United States. Chin Clin Oncol 2017;6:21.
78. Bai X, Liu Z, Shao X, Wang D, Dong E, et al. The heterogeneity of plasma miRNA profiles in hepatocellular carcinoma patients and the exploration of diagnostic circulating miRNAs for hepatocellular carcinoma. PLoS One 2019;14:e0211581.
79. Zhou J, Yu L, Gao X, Hu J, Wang J, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011;29:4781-8.
80. Xu J, Wu C, Che X, Wang L, Yu D, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011;50:136-42.
81. Qu J, Yang J, Chen M, Cui L, Wang T, et al. MicroRNA-21 as a diagnostic marker for hepatocellular carcinoma: A systematic review and meta-analysis. Pak J Med Sci 2019;35:1466-71.
82. Qi P, Cheng SQ, Wang H, Li N, Chen YF, et al. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011;6:e28486.
83. Tan Y, Ge G, Pan T, Wen D, Chen L, et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One 2014;9:e107986.
84. Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011;406:70-3.
85. Jin Y, Wong YS, Goh BKP, Chan CY, Cheow PC, et al. Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. Sci Rep 2019;9:10464.
86. Ning S, Liu H, Gao B, Wei W, Yang A, et al. miR-155, miR-96 and miR-99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma. Oncol Lett 2019;18:3381-7.
87. Teufel M, Seidel H, Kochert K, Meinhardt G, Finn RS, et al. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology 2019;156:1731-41.
88. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013;15:415-53.
89. Fiorentino FP, Macaluso M, Miranda F, Montanari M, Russo A, et al. CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer. Mol Cancer Res 2011;9:225-33.
90. Yu Y, Zuo J, Tan Q, Zar Thin K, Li P, et al. Plasma miR-92a-2 as a biomarker for small cell lung cancer. Cancer Biomark 2017;18:319-27.
91. Shi GL, Chen Y, Sun Y, Yin YJ, Song CX. Significance of serum microRNAs in the auxiliary diagnosis of non-small cell lung cancer. Clin Lab 2017;63:133-40.
92. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, et al. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 2012;130:1378-86.
93. Zhang Y, Zhang Y, Yin Y, Li S. Detection of circulating exosomal miR-17-5p serves as a novel non-invasive diagnostic marker for non-small cell lung cancer patients. Pathol Res Pract 2019;215:152466.
94. Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 2011;4:575-86.
95. Giallombardo M, Chacartegui Borras J, Castiglia M, Van Der Steen N, Mertens I, et al. Exosomal miRNA analysis in non-small cell lung cancer (NSCLC) Patients’ Plasma through qPCR: a feasible liquid biopsy tool. J Vis Exp 2016; doi: 10.3791/53900.
96. Jin X, Chen Y, Chen H, Fei S, Chen D, et al. Evaluation of tumor-derived exosomal mirna as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. Clin Cancer Res 2017;23:5311-9.
97. Zhou Y, Shen S. MiR-520f acts as a biomarker for the diagnosis of lung cancer. Medicine (Baltimore) 2019;98:e16546.
98. Zhang YL, Zhang ZL, Zhu XB, Xu L, Lu P, et al. Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer. Eur Rev Med Pharmacol Sci 2019;23:5251-9.
99. Li J, Yu M, Liu Z, Liu B. Clinical significance of serum miR-25 in non-small-cell lung cancer. Br J Biomed Sci 2019;76:111-6.
100. Bianchi F, Nicassio F, Marzi M, Belloni E, Dall’olio V, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 2011;3:495-503.
101. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.
102. Alegre E, Sammamed M, Fernandez-Landazuri S, Zubiri L, Gonzalez A. Circulating biomarkers in malignant melanoma. Adv Clin Chem 2015;69:47-89.
103. Vereecken P, Cornelis F, Van Baren N, Vandersleyen V, Baurain JF. A synopsis of serum biomarkers in cutaneous melanoma patients. Dermatol Res Pract 2012;2012:260643.
104. Solé C, Tramonti D, Schramm M, Goicoechea I, Armesto M, et al. The circulating transcriptome as a source of biomarkers for melanoma. Cancers (Basel) 2019;11.
105. Shiiyama R, Fukushima S, Jinnin M, Yamashita J, Miyashita A, et al. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Res 2013;23:366-72.
106. Fogli S, Polini B, Carpi S, Pardini B, Naccarati A, et al. Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. Tumour Biol 2017;39:1010428317701646.
107. Greenberg E, Besser MJ, Ben-Ami E, Shapira-Frommer R, Itzhaki O, et al. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers 2013;18:502-8.
108. Alegre E, Sanmamed MF, Rodriguez C, Carranza O, Martin-Algarra S, et al. Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma. Arch Pathol Lab Med 2014;138:828-32.
109. Tengda L, Shuping L, Mingli G, Jie G, Yun L, et al. Serum exosomal microRNAs as potent circulating biomarkers for melanoma. Melanoma Res 2018;28:295-303.
110. Fleming NH, Zhong J, da Silva IP, Vega-Saenz de Miera E, Brady B, et al. Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. Cancer 2015;121:51-9.
111. Tian R, Liu T, Qiao L, Gao M, Li J. Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma. Int J Clin Exp Pathol 2015;8:3097-103.
112. Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, et al. The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: a microRNA expression analysis. EBioMedicine 2015;2:671-80.
113. Van Laar R, Lincoln M, Van Laar B. Development and validation of a plasma-based melanoma biomarker suitable for clinical use. Br J Cancer 2018;118:857-66.
114. Svedman FC, Lohcharoenkal W, Bottai M, Brage SE, Sonkoly E, et al. Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma. PLoS One 2018;13:e0206942.
115. Zhang H, Xu S, Liu X. MicroRNA profiling of plasma exosomes from patients with ovarian cancer using high-throughput sequencing. Oncol Lett 2019;17:5601-7.
116. Kim S, Choi MC, Jeong JY, Hwang S, Jung SG, et al. Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas. J Cancer 2019;10:1958-67.
117. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008;110:13-21.
118. Gong L, Wang C, Gao Y, Wang J. Decreased expression of microRNA-148a predicts poor prognosis in ovarian cancer and associates with tumor growth and metastasis. Biomed Pharmacother 2016;83:58-63.
119. Marton E, Lukacs J, Penyige A, Janka E, Hegedus L, et al. Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer. J Biotechnol 2019;297:58-65.
120. Wang W, Yin Y, Shan X, Zhou X, Liu P, et al. The value of plasma-based microRNAs as diagnostic biomarkers for ovarian cancer. Am J Med Sci 2019;358:256-67.
121. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 2012;3:105-19.
123. Liu R, Chen X, Du Y, Yao W, Shen L, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012;58:610-8.
124. Nakamura S, Sadakari Y, Ohtsuka T, Okayama T, Nakashima Y, et al. Pancreatic juice exosomal microRNAs as biomarkers for detection of pancreatic ductal adenocarcinoma. Ann Surg Oncol 2019;26:2104-11.
125. Vila-Navarro E, Duran-Sanchon S, Vila-Casadesus M, Moreira L, Gines A, et al. Novel circulating miRNA signatures for early detection of pancreatic neoplasia. Clin Transl Gastroenterol 2019;10:e00029.
126. Zhu Y, Wang J, Wang F, Yan Z, Liu G, et al. Differential microRNA expression profiles as potential biomarkers for pancreatic ductal adenocarcinoma. Biochemistry (Mosc) 2019;84:575-82.
127. Kelly BD, Miller N, Sweeney KJ, Durkan GC, Rogers E, et al. A circulating microRNA signature as a biomarker for prostate cancer in a high risk group. J Clin Med 2015;4:1369-79.
128. Matin F, Jeet V, Moya L, Selth LA, Chambers S, et al. A plasma biomarker panel of four microRNAs for the diagnosis of prostate cancer. Sci Rep 2018;8:6653.
129. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, et al. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011;77:1265.e9-16.
130. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011;128:608-16.
131. Al-Qatati A, Akrong C, Stevic I, Pantel K, Awe J, et al. Plasma microRNA signature is associated with risk stratification in prostate cancer patients. Int J Cancer 2017;141:1231-9.
132. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 2012;72:1469-77.
133. Sharova E, Grassi A, Marcer A, Ruggero K, Pinto F, et al. A circulating miRNA assay as a first-line test for prostate cancer screening. Br J Cancer 2016;114:1362-6.
134. Cochetti G, Poli G, Guelfi G, Boni A, Egidi MG, et al. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role. Onco Targets Ther 2016;9:7545-53.
135. Huang X, Yuan T, Liang M, Du M, Xia S, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol 2015;67:33-41.
136. Hoey C, Ahmed M, Fotouhi Ghiam A, Vesprini D, Huang X, et al. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy. J Transl Med 2019;17:173.
137. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2011;71:550-60.
138. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011;71:326-31.
139. Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, et al. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer 2014;110:2462-71.
141. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 2016;6:e441.
142. Prada-Arismendy J, Arroyave JC, Rothlisberger S. Molecular biomarkers in acute myeloid leukemia. Blood Rev 2017;31:63-76.
143. Zhi F, Cao X, Xie X, Wang B, Dong W, et al. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. PLoS One 2013;8:e56718.
144. Fayyad-Kazan H, Bitar N, Najar M, Lewalle P, Fayyad-Kazan M, et al. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med 2013;11:31.
145. Zhi Y, Xie X, Wang R, Wang B, Gu W, et al. Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia. Int J Hematol 2015;102:296-303.
146. Tang X, Chen L, Yan X, Li Y, Xiong Y, et al. Overexpression of miR-210 is associated with poor prognosis of acute myeloid leukemia. Med Sci Monit 2015;21:3427-33.
147. Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol 2013;31:2086-93.
148. Fang Z, Wang X, Wu J, Xiao R, Liu J. High serum extracellular vesicle miR-10b expression predicts poor prognosis in patients with acute myeloid leukemia. Cancer Biomark 2019;27:1-9.
149. Guo Y. Clinical significance of serum MicroRNA-203 in patients with acute myeloid leukemia. Bioengineered 2019;10:345-52.
150. Jabber Al-Obaidi MS, Martineau M, Bennett CF, Franklin IM, Goldstone AH, et al; Medical Research Council Adult Leukaemia Working Party. ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemia. Leukemia 2002;16:669-74.
151. Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev 2012;26:123-35.
152. Luna-Aguirre CM, de la Luz Martinez-Fierro M, Mar-Aguilar F, Garza-Veloz I, Trevino-Alvarado V, et al. Circulating microRNA expression profile in B-cell acute lymphoblastic leukemia. Cancer Biomark 2015;15:299-310.
153. Ishihara K, Sasaki D, Tsuruda K, Inokuchi N, Nagai K, et al. Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia. Cancer Epidemiol 2012;36:560-5.
154. Swellam M, Hashim M, Mahmoud MS, Ramadan A, Hassan NM. Aberrant expression of some circulating miRNAs in childhood acute lymphoblastic leukemia. Biochem Genet 2018;56:283-94.
155. Amaya-Chanaga CI, Rassenti LZ. Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers. Best Pract Res Clin Haematol 2016;29:79-89.
156. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood 2013;122:1891-9.
157. Yeh YY, Ozer HG, Lehman AM, Maddocks K, Yu L, et al. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood 2015;125:3297-305.
158. Stamatopoulos B, Van Damme M, Crompot E, Dessars B, Housni HE, et al. Opposite prognostic significance of cellular and serum circulating microRNA-150 in patients with chronic lymphocytic leukemia. Mol Med 2015;21:123-33.
159. Marcucci G, Mrozek K, Radmacher MD, Bloomfield CD, Croce CM. MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias. Best Pract Res Clin Haematol 2009;22:239-48.
160. Skrabek P, Turner D, Seftel M. Epidemiology of non-Hodgkin lymphoma. Transfus Apher Sci 2013;49:133-8.
161. Morra E. The biological markers of non-Hodgkin’s lymphomas: their role in diagnosis, prognostic assessment and therapeutic strategy. Int J Biol Markers 1999;14:149-53.
162. Fang C, Zhu DX, Dong HJ, Zhou ZJ, Wang YH, et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol 2012;91:553-9.
163. Yuan WX, Gui YX, Na WN, Chao J, Yang X. Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients. Oncol Lett 2016;11:423-32.
164. Jones CI, Zabolotskaya MV, King AJ, Stewart HJ, Horne GA, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer 2012;107:1987-96.
165. Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, et al. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J 2012;2:e53.
166. Huang JJ, Yu J, Li JY, Liu YT, Zhong RQ. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma. Med Oncol 2012;29:2402-8.
167. Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R. Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma 2013;54:189-91.
168. Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 2014;99:511-8.
169. Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, et al. Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia 2014;28:1922-6.
170. Qu X, Zhao M, Wu S, Yu W, Xu J, et al. Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma. Med Oncol 2014;31:219.
171. Hao M, Zang M, Zhao L, Deng S, Xu Y, et al. Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis. Oncotarget 2016;7:19589-600.
172. Hao M, Zang M, Wendlandt E, Xu Y, An G, et al. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer 2015;136:1835-44.
173. Jung SH, Lee SE, Lee M, Kim SH, Yim SH, et al. Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. Haematologica 2017;102:e456-e9.
174. Navarro A, Diaz T, Tovar N, Pedrosa F, Tejero R, et al. A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget 2015;6:1874-83.
175. Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, et al. Circulating serum microRNA-130a as a novel putative marker of extramedullary myeloma. PLoS One 2015;10:e0137294.
